Drug Topics
NOVEMBER 24, 2023
Study authors recommend that healthcare personnel consider prioritizing influenza vaccination for patients with recent cardiovascular diseases (CVDs) in light of new evidence.
Pharmacy Times
NOVEMBER 24, 2023
In part 2 of this series, trauma-informed pharmacist Helen Sairany, PharmD, MBA, discusses the physical manifestations of burnout.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
NOVEMBER 24, 2023
Reproductive-aged women who consume energy drinks should be aware of the potential risks, as energy drink consumption has been linked to adverse pregnancy outcomes.
Pharmacy Times
NOVEMBER 24, 2023
For pharmacists and pharmacy technicians, who work diligently to ensure our health and well-being, choosing the perfect holiday gift can be a thoughtful way to express gratitude and brighten their season.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
STAT
NOVEMBER 24, 2023
Reports this week that China is experiencing a surge in respiratory infections in young children triggered flashbacks of the start of the Covid-19 pandemic among infectious disease watchers. But a rapidly organized meeting Thursday between the World Health Organization and health officials in China assuaged much of that concern. The evidence presented to the WHO team pointed to what’s sometimes called an immunity gap that was created by the pandemic.
pharmaphorum
NOVEMBER 24, 2023
How to optimise commercial-scale ATMP manufacturing through automation Mike.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
European Pharmaceutical Review
NOVEMBER 24, 2023
Amgen’s new immunotherapeutic agent Tarlatamab has been shown in a Phase II trial to provide sustained anti-tumour activity in 40 percent of the small cell lung cancer patients. The international DeLLphi-301study was investigated as a new anti-cancer treatment option for patients previously considered to be beyond treatment. Results from the trial were published in the New England Journal of Medicine.
STAT
NOVEMBER 24, 2023
I had only lived in Kibera for 15 minutes when I saw a police officer and was arrested. But it would be years before I saw a real doctor. In 2001, at the age of 13, I had come to Kenya’s largest informal settlement on the outskirts of Nairobi with my sister. When we arrived at 3 a.m., we dutifully called my uncle from a phone booth to pick us up.
pharmaphorum
NOVEMBER 24, 2023
International Health Partners' Christmas campaign: Working with pharma for patients worldwide Nicole.
STAT
NOVEMBER 24, 2023
A few years ago, I worked with a patient close to 100 years old. She had diabetes for most of her adult life, which affected circulation in her foot. Without circulation to her foot, it turned black, and then her calf turned black. In this stage of deterioration, no one is talking about treating metabolic disease; often, patients even stop checking their blood sugar.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmaceutical Technology
NOVEMBER 24, 2023
Bayer announced the launch of a Berlin, Germany-based manufacturing facility to meet future demands from the US, China and Europe.
Pharmafile
NOVEMBER 24, 2023
Alladapt Immunotherapeutics has announced that ADP101 has received Fast Track Designation from the US Food and Drug Administration (FDA) as a treatment for one or more food allergens. ADP101 is currently the most advanced multi-food oral immunotherapy (mOIT) candidate in development, and there are currently no FDA-approved OIT treatments for multi-food allergy to foods other […] The post Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment appea
European Pharmaceutical Review
NOVEMBER 24, 2023
Novo Nordisk is investing over €2.1 billion (16 billion Danish kroner) to expand its production site in Chartres, France, supporting manufacture of its products for serious chronic diseases. Novo Nordisk’s multi-billion facility expansion This financial commitment will greatly strengthen manufacturing capacity, more than doubling the site’s footprint.
Outsourcing Pharma
NOVEMBER 24, 2023
Calliditas Therapeutics AB announced today (November 24) that its partner Everest Medicines has revealed that China's National Medical Products Administration (NMPA) has approved Nefecon.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
European Pharmaceutical Review
NOVEMBER 24, 2023
The European Commission has granted a label expansion of the combination treatment KAFTRIO ® (ivacaftor/tezacaftor/elexacaftor) with ivacaftor, for children aged two to five years old with cystic fibrosis. The treatment from Vertex Pharmaceuticals is indicated for individuals who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator ( CYSTIC FIBROSISTR ) gene.
Outsourcing Pharma
NOVEMBER 24, 2023
The Janssen Pharmaceutical Companies of Johnson & Johnson announced last week (November 23) the submission of a type 2 extension of indication application to the European Medicines Agency (EMA).
pharmaphorum
NOVEMBER 24, 2023
NHS Confederation, ABPI say break down barriers to partnerships and change the lives of millions Nicole.
Pharmaceutical Technology
NOVEMBER 24, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for F. Hoffmann-La Roche here.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
NOVEMBER 24, 2023
Intellectual property: Striking the balance Mike.
Pharmaceutical Technology
NOVEMBER 24, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for Johnson & Johnson here.
Pharmafile
NOVEMBER 24, 2023
Freeline Therapeutics has announced that it has entered into a definitive agreement with newly established portfolio company Syncona, in which Syncona will acquire Freeline in an all-cash transaction. Syncona will pay $6.50 per share, or an approximate total of $28.3m. The acquisition is expected to close in the first quarter of 2024, although it is […] The post Syncona to acquire Freeline Therapeutics for $28.3m appeared first on Pharmafile.
Pharmaceutical Technology
NOVEMBER 24, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for Amgen here.
Pharma Times
NOVEMBER 24, 2023
Around 3,200 new cases of cervical cancer are diagnosed in the UK every year - News - PharmaTimes
Pharmaceutical Technology
NOVEMBER 24, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for Novartis here.
Outsourcing Pharma
NOVEMBER 24, 2023
The Janssen Pharmaceutical Companies of Johnson & Johnson announced last week (November 23) the submission of a type 2 extension of indication application to the European Medicines Agency (EMA).
Pharmaceutical Technology
NOVEMBER 24, 2023
Access and buy GlobalData’s databook on the latest filings and grants activity for Bristol-Myers Squibb here.
BioPharm
NOVEMBER 24, 2023
Looking at the role that RSV and pediatric medical practices play in drug shortages.
Pharmaceutical Technology
NOVEMBER 24, 2023
The Sosei Heptares oral IBD drug was first licensed to GSK in 2020 and is currently in Phase I clinical development.
BioPharm
NOVEMBER 24, 2023
The largest biotech hub is set to be built in Lithuania by Northway Group.
Pharmaceutical Technology
NOVEMBER 24, 2023
Vertex Pharmaceuticals has obtained approval from EC) for the label expansion of Kaftrio plus ivacaftor to treat children with CF.
Pharma Times
NOVEMBER 24, 2023
The findings could benefit patients living with neurodegenerative conditions - News - PharmaTimes
Pharmaceutical Technology
NOVEMBER 24, 2023
The expansion comes as Novo is trying to maintain strong growth in T2D after the launch of Eli Lilly’s Zepbound this month.
DiversifyRx
NOVEMBER 24, 2023
While DSCSA (the Drug Supply Chain Security Act) enforcement is postponed until November 2024, it is critical to move forward in becoming compliant sooner rather than later. In the world of running a pharmacy, patient safety is Everything. To achieve this, the U.S. pharmaceutical industry is wrapped up in a web of regulations, and one of the most significant in recent years is the Drug Supply Chain Security Act (DSCSA).
Expert insights. Personalized for you.
232 
Let's personalize your content